Intrathecal chemotherapy

ApprovedSmall molecule

PPrincess Maxima Center for Pediatric Oncology

Intrathecal chemotherapy is one of 101 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Childhood Acute Lymphoblastic LeukemiaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Acute LeukemiaActive, not recruiting

Leptomeningeal MetastasisActive, not recruiting

Childhood Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Acute LeukemiaPhase 1/Phase 2

Active, not recruiting

Leptomeningeal MetastasisApproved

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Vanflyta

Daiichi Sankyo

Phase 3

13 2

Nexavar

Bayer

Phase 3

12 3

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

12 4

Velcade

SShilpa Grover, MD, MPH

Phase 3

11 5

Tabloid

Akero Therapeutics

Phase 3

2 6

Intrathecal chemotherapy

PPrincess Maxima Center for Pediatric Oncology

Approved

1 7

Active Comparator

Moderna

Phase 3

1 8

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Phase 3

1 9

Iomab-B

AActinium Pharmaceuticals

Phase 3

1 10

PR1 Leukemia Peptide Vaccine

TThe Vaccine Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Leptomeningeal Metastasis

NCT06230055

Q2 2027

Phase 1Recruiting

Acute Myeloid Leukemia

NCT06177067

Q2 2029

Phase 1/2Recruiting

Hematological Malignancies

NCT05658640

Q4 2029

Phase 2Recruiting

Leptomeningeal Metastases

NCT07304739

Clinical

Trials by Indication[1]

Hematological Malignancies5 trials

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Not yet recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT07175415·42 enrolled

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Withdrawn·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT05740449

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT05745714·26 enrolled

Show 2 more trials

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT05658640·26 enrolled

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Recruiting·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT05751044·26 enrolled

Acute Leukemia2 trials

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05521087

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Terminated· Roche logo

Roche·Phase 1/2·NCT04029688·38 enrolled

Leptomeningeal Metastasis1 trial

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

Recruiting·FFudan University·Phase 4·NCT06230055·37 enrolled

Childhood Acute Lymphoblastic Leukemia1 trial

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01324180·14 enrolled

Leptomeningeal Metastases1 trial

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07304739·30 enrolled

1 more indication

Acute Myeloid Leukemia1 trial

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT06177067·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Intrathecal chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intrathecal chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intrathecal chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Princess Maxima Center for Pediatric Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPrincess Maxima Center for Pediatric Oncology

Intrathecal chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q2 2029

Q4 2029

Trials by Indication[1]

Hematological Malignancies5 trials

Acute Leukemia2 trials

Leptomeningeal Metastasis1 trial

Childhood Acute Lymphoblastic Leukemia1 trial

Leptomeningeal Metastases1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News